Does Vandetanib Cause Heart Rhythm Changes?
Yes, vandetanib (Zactima or Caprelsa), a tyrosine kinase inhibitor for medullary thyroid cancer, carries a black box warning for QT interval prolongation, a heart rhythm change that can lead to torsades de pointes and sudden death. This risk stems from its effects on cardiac potassium channels, particularly hERG, which delays ventricular repolarization.[1][2]
How Common Is This Side Effect?
QT prolongation occurs in about 10-25% of patients on vandetanib, with severe cases (QTc >500 ms) in 5-10%. Prolongation often starts within weeks of treatment and worsens with dose increases. In clinical trials like ZETA, 18% of patients had QTc >500 ms, and 35% experienced any QT prolongation.[1][3]
What Factors Increase the Risk?
Higher doses (300 mg daily), female sex, older age, low potassium or magnesium, congenital long QT syndrome, and concurrent use of other QT-prolonging drugs (e.g., antiarrhythmics, certain antibiotics, or antidepressants) amplify risk. Hypokalemia from vandetanib-induced diarrhea further contributes.[1][2][4]
How Is It Monitored and Managed?
Guidelines require baseline ECG and serum electrolytes before starting, then ECGs at 2-4 weeks, 8-12 weeks, and periodically. Correct electrolytes, reduce dose to 200 mg if QTc 451-500 ms, or discontinue if >500 ms or symptomatic (e.g., palpitations, syncope). Avoid strong CYP3A4 inhibitors that raise vandetanib levels.[1][4]
What Do Patients Report?
Real-world data and FDA adverse event reports note arrhythmias, ventricular tachycardia, and cardiac arrest in <1-2% of cases, often linked to unmonitored polypharmacy. Patients frequently ask about symptoms like dizziness or fainting, which signal urgent evaluation.[2][3]
Are There Safer Alternatives?
Compared to other TKIs like cabozantinib (Cabometyx) or lenvatinib (Lenvima) for thyroid cancer, vandetanib has higher QT risk but similar efficacy. Selpercatinib (Retevmo) or pralsetinib (Gavreto) target RET fusions with less cardiac toxicity. Choice depends on mutation status and comorbidities.[3][5]
Sources
[1]: FDA Label for Caprelsa (vandetanib)
[2]: Drugs.com - Vandetanib Side Effects
[3]: ZETA Trial - NEJM 2012
[4]: NCCN Guidelines - Thyroid Cancer
[5]: DrugPatentWatch.com - Vandetanib Patents